BMS Secures Phase 3 Wins for Admilparant and RYZ101 Amid Patent Cliff Pressures
Bristol Myers Squibb (BMS) reported positive Phase 3 results for two experimental drugs, admilparant and RYZ101, as it seeks to offset the impending loss of exclusivity for its blockbuster products Eliquis and Opdivo. While both trials met their primary endpoints, the market reaction was mixed, with BMS stock initially rising before falling, reflecting investor caution regarding safety data and dose efficacy.